Format

Send to

Choose Destination
See comment in PubMed Commons below
PLoS One. 2014 Jun 20;9(6):e98013. doi: 10.1371/journal.pone.0098013. eCollection 2014.

Prevalence of metabolic syndrome in COPD patients and its consequences.

Author information

1
Department of Respiratory Medicine, Maastricht University Medical Center + (MUMC+), Maastricht, the Netherlands; Program Development Center (CIRO), Center of expertise for chronic organ failure, Horn, the Netherlands; Department of Respiratory and Critical Care Medicine and Ludwig Boltzmann Institute for COPD and Pulmonary Epidemiology, Otto Wagner Hospital, Vienna, Austria.
2
Program Development Center (CIRO), Center of expertise for chronic organ failure, Horn, the Netherlands.
3
Division of Medical Nutrition Education, School of Allied Health Professions, University of Nebraska Medical Center, Ohmaha, Nebraska, United States of America.
4
Inflammation Neuroscience and Respiratory, AstraZeneca, Molndal, Sweden.
5
Department of Respiratory Medicine, Maastricht University Medical Center + (MUMC+), Maastricht, the Netherlands; Program Development Center (CIRO), Center of expertise for chronic organ failure, Horn, the Netherlands.

Abstract

BACKGROUND:

The prevalence of metabolic syndrome in COPD patients and its impact on patient related outcomes has been little studied. We evaluated the prevalence of metabolic syndrome and clinical and functional characteristics in patients with COPD and healthy subjects.

METHODS:

228 COPD patients and 156 healthy subjects were included. Metabolic syndrome was defined using criteria of the IDF. In all patients spirometry, body composition, functional exercise performance, and mood and health status were assessed. Groups were stratified for BMI and gender.

RESULTS:

Metabolic syndrome was present in 57% of the COPD patients and 40% of the healthy subjects. After stratification for BMI, presence of metabolic syndrome in patients with a BMI ≥25 kg/m2 was higher than in healthy peers. Patients with metabolic syndrome and a BMI <25 kg/m2 had higher BMI, fat free mass index and bone mineral density, and a lower 6MWD than the BMI matched patients without metabolic syndrome. Spirometry, maximal ergometry, mood and health status, and blood gases were not different between those groups. In COPD patients with metabolic syndrome self-reported co-morbidities and medication use were higher than in those without.

CONCLUSION:

Metabolic syndrome is more prevalent in overweight or obese COPD patients than in BMI matched healthy subjects. Metabolic syndrome did not additionally impact patients' functional outcomes, but did impact the prevalence of co-morbidities.

PMID:
24950070
PMCID:
PMC4064974
DOI:
10.1371/journal.pone.0098013
[Indexed for MEDLINE]
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Public Library of Science Icon for PubMed Central
    Loading ...
    Support Center